The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment

Opinion
Video

Rahul Banerjee, MD, FACP, discusses how the emergence of CAR T-cell therapy has impacted the multiple myeloma treatment landscape by addressing unmet needs and improving patients’ quality of life.

Video content above is prompted by the following questions:

  • How has the emergence of CAR T-cell therapy impacted the treatment paradigm for relapsed/refractory multiple myeloma?
    • Does this therapy address an unmet need in R/R MM?
    • How do you manage patients who may not meet the eligibility criteria for CAR T-cell therapy but still have a significant unmet need for effective treatment options?
Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content